| • New Biologicals Development Center in Biberach, Germany bundles biologics development, increases capacity and expands clinical supply network
• Increased development capacities reflect research pipeline growth and free up capacity for contract manufacturing
• Focus on therapeutic areas with high unmet medical need such as cancer and immunological diseases
BIBERACH, Germany-Friday 22 June 2018 [ AETOS Wire ]
(BUSINESS WIRE)-- Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center.
“The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.”
The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning in 2020, the new building will be home to 500 employees. This is an increase of about 100 employees in biologicals development compared to today.
The new BDC adds to a number of major recent investments into the global Boehringer Ingelheim biopharmaceuticals development network aiming to further increase the company’s mammalian cell culture capabilities in this important area, including the large scale biopharmaceuticals facility in Vienna, Austria, a new biopharmaceuticals facility in Shanghai, China, and the expansion of existing large scale biopharmaceutical capacities in Fremont, CA, USA, leading to an overall increase of investment in biopharmaceutical research, development and production.
Boehringer Ingelheim has developed biopharmaceuticals, such as a humanized antibody fragment that selectively reverts the effect of an oral anticoagulant prior to urgent procedures / emergency surgery or in uncontrolled bleeding, a first-in-class Interleukin-36 receptor antibody is being tested among others for special forms of psoriasis (generalized pustular psoriasis and palmoplantar pustulosis) as well as ulcerative colitis and crohn’s disease and several antibodies under investigation for difficult to treat cancers. Boehringer Ingelheim is committing more than 20% of its human pharma net sales to Research & Development. More than 8,000 employees work in four R&D centers of excellence on a highly innovative pipeline, 50% of which is anchored in external innovation.
Boehringer Ingelheim BioXcellence™ is a leader in biopharmaceutical contract manufacturing for large volume products, manufacturing 29 biopharmaceuticals for industry partners from around the world. These include monoclonal antibodies for oncology and immunology, interferons and other targeted therapies.
Please click on the link for ‘Notes to Editors’:http://www.boehringer-ingelheim.com/press-release/new-biologicals-development-center-germany-announced
Contacts
Boehringer Ingelheim
Matthias Reinig
Corporate Topics
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 184855
press@boehringer-ingelheim.com
or
Boehringer Ingelheim
Dr. Reinhard Malin
Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com
Permalink : http://aetoswire.com/news/boehringer-ingelheim-bolsters-biologics-research-and-development-with-230-million-euro-investment-in-new-development-center/en
|
